NovoCure (STU:038) Inventories, Finished Goods : €18.7 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is NovoCure Inventories, Finished Goods?

NovoCure's quarterly finished goods declined from Sep. 2023 (€17.7 Mil) to Dec. 2023 (€16.6 Mil) but then increased from Dec. 2023 (€16.6 Mil) to Mar. 2024 (€18.7 Mil).

NovoCure's annual finished goods increased from Dec. 2021 (€13.0 Mil) to Dec. 2022 (€14.9 Mil) and increased from Dec. 2022 (€14.9 Mil) to Dec. 2023 (€16.6 Mil).

NovoCure Inventories, Finished Goods Historical Data

The historical data trend for NovoCure's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Inventories, Finished Goods Chart

NovoCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

11.98

14.26

12.98

14.86

16.59

NovoCure Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															16.19	14.57	17.72	16.59	18.66

NovoCure Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

NovoCure (STU:038) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

NVCR:USA

Address

Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF

Website

https://www.novocure.com

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines